Human PARC/CCL18 (Pulmonary Activation Regulated Chemokine) CLIA Kit
The Human PARC/CCL18 (Pulmonary Activation Regulated Chemokine) CLIA Kit is specifically designed for the precise measurement of PARC/CCL18 levels in human samples including serum, plasma, and cell culture supernatants. This kit is known for its exceptional sensitivity and specificity, ensuring accurate and reproducible results for varied research applications.PARC/CCL18 is a key chemokine involved in regulating immune responses in the lungs, particularly in pulmonary diseases such as asthma, chronic obstructive pulmonary disease (COPD), and fibrotic lung disorders.
Its role in inflammation and immune cell recruitment makes it a valuable biomarker for understanding and potentially treating these respiratory conditions.With the Human PARC/CCL18 CLIA Kit, researchers can confidently study the role of this chemokine in pulmonary diseases, paving the way for the development of novel therapeutic approaches aimed at targeting PARC/CCL18-mediated pathways.
Product Name:
Human PARC/CCL18 (Pulmonary Activation Regulated Chemokine) CLIA Kit
SKU:
HUES00727
Target:
Human PARC/CCL18 (Pulmonary Activation Regulated Chemokine)
Size:
96T
Assay type:
Sandwich
Assay time:
4.5h
Sensitivity:
9.38 pg/mL
Detection range:
15.63-1000 pg/mL
Kit component:
Component
Quantity (24 Assays)
Quantity (96 Assays)
Storage
CLIA Plate
8 wells x 3 strips
8 wells x 12 strips
-20°C, 6 months
Reference Standard
1 vial
2 vials
Concentrated Biotinylated Detection Ab (100×)
1 vial, 60 µL
1 vial, 120 µL
Concentrated HRP Conjugate (100×)
1 vial, 60 µL
1 vial, 120 µL
-20°C (shading light), 6 months
Reference Standard & Sample Diluent
1 vial, 20 mL
1 vial, 20 mL
4°C, 6 months
Biotinylated Detection Ab Diluent
1 vial, 14 mL
1 vial, 14 mL
HRP Conjugate Diluent
1 vial, 14 mL
1 vial, 14 mL
Concentrated Wash Buffer (25×)
1 vial, 30 mL
1 vial, 30 mL
Substrate Reagent A
1 vial, 5 mL
1 vial, 5 mL
4°C (shading light)
Substrate Reagent B
1 vial, 5 mL
1 vial, 5 mL
Desiccant
1
1
Plate Sealer
5 pieces
5 pieces
Product Description
1 copy
1 copy
This CLIA kit uses the Sandwich-CLIA principle. The micro CLIA plate provided in this kit has been pre-coated with an antibody specific to Human PARC/CCL18. Standards or samples are added to the micro CLIA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human PARC/CCL18 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human PARC/CCL18, biotinylated detection antibody and Avidin-HRP conjugate will appear fluorescence. The Relative light unit (RLU) value is measured by the Chemiluminescence immunoassay analyzer. The RLU value is positively associated with the concentration of Human PARC/CCL18. You can calculate the concentration of Human PARC/CCL18 in the samples by comparing the RLU value of the samples to the standard curve.
Linearity:
Serum (n=5)
EDTA plasma (n=5)
Cell culture media (n=5)
1:2
Range (%)
99-113
95-108
100-115
Average (%)
106
100
107
1:4
Range (%)
100-115
85-98
100-114
Average (%)
109
91
105
1:8
Range (%)
85-100
89-101
93-104
Average (%)
91
94
99
1:16
Range (%)
90-102
85-101
90-100
Average (%)
97
92
95
Recovery:
Sample Type
Range (%)
Average Recovery (%)
Serum (n=5)
95-107
101
EDTA plasma (n=5)
97-109
104
Cell culture media (n=5)
97-111
103
Precision:
Intra-assay Precision
Inter-assay Precision
Sample
1
2
3
1
2
3
n
20.0
20.0
20.0
20.0
20.0
20.0
Mean (ng/mL)
49.95
146.96
427.75
54.47
139.26
418.11
Standard deviation
6.15
15.86
27.5
5.82
15.76
28.81
C V (%)
12.31
10.79
6.43
10.68
11.32
6.89
Sample type &Sample volume:
Serum, plasma and other biological fluids; 100μL
Reproducibility:
Both intra-CV and inter-CV are < 15%.
Application:
This CLIA kit applies to the in vitro quantitative determination of Human PARC/CCL18 concentrations in Serum, plasma and other biological fluids.
Specificity:
This kit recognizes Human PARC/CCL18 in samples. No significant cross-reactivity or interference between Human PARC/CCL18 and analogues was observed.
